Cannovex

Agoralaan Building Abis /
3590 Diepenbeek
BE
Cannovex
Foundation date
06/08/2016
Sector
#Biotechnology - otherSubsector
Therapeutic areas
- #Digestive system
- #Diseases of the blood and blood-forming organs - immune disorders
- #Diseases of the eye
- #Diseases of the nervous system
- #Endocrine - nutritional and metabolic diseases
- #Mental and behavioural disorders
- #Musculoskeletal system and connective tissue
- #Neoplasms / cancer / oncology
- #Respiratory system
- #Skin and subcutaneous tissue
Cannovex is a Benelux-origin biotech company which develops cannabinoid-based medicines to improve the lives of patients worldwide. Over a two year period, Cannovex has conducted an in-depth and exhaustive study of medical literature on this subject, and continues to monitor all scientific publications. These efforts establish Cannovex as the designated conversation partner, sounding board and source of information on cannabinoid medicines for all stakeholders.
Based on the insights resulting from the above-mentioned research, Cannovex is now planning the development of cannabinoid-based medicines in specific therapeutic areas and for well-defined indications. Cannovex aims to set up clinical studies, in collaboration with EU university hospitals, to provide proofs of concept (PoC). Based on these PoCs, Cannovex will explore partnerships with pharmaceutical companies to conduct end-stage clinical trials, to apply for market authorisation with European Medicines Agency (EMA) and similar authorities, and to bring our cannabinoid medicinal products to the markets worldwide.
Upcoming events
All events-
1212 '23
BioFIT 2023
Event by: Eurasanté -
0602 '24
Discovery to Innovation in Animal Health - 2024
Event by: Ghent University, Provaxs, Paul Dick & Associates -
3011 '23
The GxP Academy: Aseptische Training en werken in LAF/Biosafety Cabinet
Event by: Advipro
Latest news
More news-
argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia
20 hours ago
Read more
-
Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion
Wednesday November 22nd 2023
Read more
-
argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis
Thursday November 16th 2023
Read more
Jobs
More jobs-
-
-
27/11/23
Antwerp, Brussels, East Flanders, Hainaut, Liège, Limburg, Luxembourg, Namur, Flemish Brabant, Walloon Brabant, West Flanders, Remote
Project Manager Life Science & IVD
Permanent
Thema Group Belgium
More info?
Ellen Telleir
Communication Coordinator